{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:35:19Z","timestamp":1790429719946,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10067-024-07070-8","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T02:01:26Z","timestamp":1721095286000},"page":"2817-2823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-0859","authenticated-orcid":false,"given":"Marta","family":"Novella-Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-6601","authenticated-orcid":false,"given":"Virginia","family":"Ruiz-Esquide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-2615","authenticated-orcid":false,"given":"Natalia","family":"L\u00f3pez-Juanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6781-0153","authenticated-orcid":false,"given":"Chafik Alejandro","family":"Chacur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-8016","authenticated-orcid":false,"given":"Irene","family":"Monjo-Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-0458","authenticated-orcid":false,"given":"Laura","family":"Nu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6953-409X","authenticated-orcid":false,"given":"Diana","family":"Peiteado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-3714","authenticated-orcid":false,"given":"Alejandro","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1628-5042","authenticated-orcid":false,"given":"Elisa","family":"Fern\u00e1ndez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Sanz-Jard\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6429-7470","authenticated-orcid":false,"given":"M\u00f3nica","family":"Kafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-3806","authenticated-orcid":false,"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-9047","authenticated-orcid":false,"given":"Chamaida","family":"Plasencia-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-7062","authenticated-orcid":false,"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"7070_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC et al (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80:31\u201335","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7070_CR2","first-page":"1114","volume":"41","author":"M Novella-Navarro","year":"2023","unstructured":"Novella-Navarro M, Ruiz-Esquide V, Torres-Ortiz G, Chacur CA, Tornero C, Fern\u00e1ndez-Fern\u00e1ndez E et al (2023) A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification. Clin Exp Rheumatol 41(5):1114\u20131119","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"7070_CR3","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","volume":"60","author":"S Takanashi","year":"2021","unstructured":"Takanashi S, Kaneko Y, Takeuchi T (2021) Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford) 60(11):5247\u20135256","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7070_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001511","volume":"7","author":"NMT Roodenrijs","year":"2021","unstructured":"Roodenrijs NMT, Kedves M, Hamar A, Nagy G, van Laar JM, van der Heijde D et al (2021) Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open 7(1):e001511","journal-title":"RMD Open"},{"issue":"1","key":"7070_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","volume":"17","author":"MH Buch","year":"2021","unstructured":"Buch MH, Eyre S, McGonagle D (2021) Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol 17(1):17\u201333","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"7070_CR6","doi-asserted-by":"publisher","first-page":"e002387","DOI":"10.1136\/rmdopen-2022-002387","volume":"8","author":"Y Tan","year":"2022","unstructured":"Tan Y, Buch MH (2022) Difficult-to-treat rheumatoid arthritis: current position and considerations for next steps. RMD Open 8(2):e002387","journal-title":"RMD Open"},{"key":"7070_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001512","volume":"7","author":"NMT Roodrenrijs","year":"2021","unstructured":"Roodrenrijs NMT, Hamar A, Kedves M, Nagy G, Van Laar JM, van der Heijde D et al (2021) Pharmacological and non-pharmacological therapeutic strategies in diffciult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat-rheumatoid arthritis. RMD Open 7:e001512","journal-title":"RMD Open"},{"issue":"1","key":"7070_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","volume":"24","author":"S Ochi","year":"2022","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y (2022) Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther 24(1):61","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"7070_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/rheumatology\/keab248","volume":"61","author":"C Norris-Grey","year":"2022","unstructured":"Norris-Grey C, Cambridge G, Moore S, Reddy V, Leandro M (2022) Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020. Rheumatology (Oxford) 61(2):591\u2013596","journal-title":"Rheumatology (Oxford)"},{"key":"7070_CR10","doi-asserted-by":"publisher","first-page":"l67","DOI":"10.1136\/bmj.l67","volume":"364","author":"JE Gottenberg","year":"2019","unstructured":"Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X (2019) French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ 364:l67","journal-title":"BMJ"},{"key":"7070_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D, L\u00f8rup EH, Nielsen ML, Nymand L et al (2022) Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum 53:151979","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"7070_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40744-021-00285-0","volume":"8","author":"DA Pappas","year":"2021","unstructured":"Pappas DA, Blachley T, Best JH, Zlotnick S, Reiss WG, Emeanuru K et al (2021) Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry. Rheumatol Ther 8(1):467\u2013481","journal-title":"Rheumatol Ther"},{"issue":"2","key":"7070_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40744-020-00201-y","volume":"7","author":"JH Best","year":"2020","unstructured":"Best JH, Vlad SC, Tominna L, Abbass I (2020) Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic. Rheumatol Ther 7(2):345\u2013355","journal-title":"Rheumatol Ther"},{"issue":"1","key":"7070_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","volume":"22","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2020) Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 22(1):142","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"7070_CR15","doi-asserted-by":"publisher","first-page":"1176613","DOI":"10.3389\/fmed.2023","volume":"28","author":"C Baldi","year":"2023","unstructured":"Baldi C, Berlengiero V, Falsetti P, Cartocci A, Conticini E, D\u2019Alessandro R et al (2023) Baricitinib retention rate: \u201creal-life\u201d data from a mono-centric cohort of patients affected by rheumatoid arthritis. Front Med (Lausanne) 28(10):1176613. https:\/\/doi.org\/10.3389\/fmed.2023","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"7070_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F et al (2019) Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA 322(4):315\u2013325","journal-title":"JAMA"},{"issue":"1","key":"7070_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41598-021-04075-0","volume":"12","author":"K Ebina","year":"2022","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2022) Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep 12(1):134","journal-title":"Sci Rep"},{"issue":"5","key":"7070_CR18","first-page":"1034","volume":"41","author":"JY Jung","year":"2023","unstructured":"Jung JY, Lee E, Kim JW, Suh CH, Kim HA (2023) Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol 41(5):1034\u20131041","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"7070_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13075-020-2100-y","volume":"22","author":"G Cagnotto","year":"2020","unstructured":"Cagnotto G, Willim M, Nilsson J\u00c5, Compagno M, Jacobsson LTH, Saevarsdottir S, Turesson C (2020) Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register. Arthritis Res Ther 22(1):15","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"7070_CR20","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s10067-022-06176-1","volume":"41","author":"R Alten","year":"2022","unstructured":"Alten R, Mariette X, Flipo RM, Caporali R, Buch MH, Patel Y et al (2022) Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clin Rheumatol 41(8):2361\u20132373","journal-title":"Clin Rheumatol"},{"issue":"4","key":"7070_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL (2016) Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. Arthritis Care Res (Hoboken) 68(4):432\u2013439","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"7070_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003382","volume":"9","author":"M Novella-Navarro","year":"2023","unstructured":"Novella-Navarro M, Cabrera-Alarc\u00f3n J, L\u00f3pez-Juanes N, Villalba A, Fern\u00e1ndezFern\u00e1ndez E, Monjo I et al (2023) Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b\/tsDMARD treatment. RMD Open 9(3):e003382","journal-title":"RMD Open"},{"key":"7070_CR23","doi-asserted-by":"publisher","first-page":"1759720X2211240","DOI":"10.1177\/1759720X221124028","volume":"14","author":"M Navarro-Novella","year":"2022","unstructured":"Navarro-Novella M, Benavent D, Esquide-Ruiz V, Tornero C, Almir\u00f3n-Diaz M, Chacur CA, Peiteado D, Villalba A, Sanmart\u00ed R, Rodr\u00edguez-Plasencia C, Balsa A (2022) Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis. Ther Adv Musculoskelet Dis 14:1759720X2211240","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7070_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110655","volume":"122","author":"H Guo","year":"2023","unstructured":"Guo H, Li L, Liu B, Lu P, Cao Z, Ji X et al (2023Sep) Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis. Int Immunopharmacol 122:110655","journal-title":"Int Immunopharmacol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07070-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07070-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07070-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T09:10:20Z","timestamp":1723885820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07070-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7070"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07070-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committ\u00e9e of La Paz University Hospital, Madrid, Spain: HULP PI-1155 (june 2011) and all patients signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"M Novella-Navarro reports grants from UCB, Galapagos and Lilly outside the submitted work. R. Sanmart\u00ed reports grants from Abbvie, Gebro-Pharma, Lilly, MSD, Pfizer, Sanofi and Roche outside the submitted work. C Plasencia-Rodr\u00edguez reports grants from Abbvie, Pfizer, Novartis, Lilly and Roche outside the submitted work. A Villalba reports grants form Pfizer, A Balsa reports grants from Abbvie, Amgen, Pfizer, Galapagos, Novartis, Gilead, BMS, Nordic, Sanofi, Sandoz, Lilly, UCB and Roche outside the submitted work. The other authors have declared no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}